TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8640909

Group type: EXPERIMENTAL
Intervention: Sunflower oil-based diet (SO)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low erucic acid rapeseed oil-based diet (RO)
Number of subjects: 59
Study: 1752117

Group type: EXPERIMENTAL
Intervention: Bradykinin (0.1 to 10 nmol in 10 microliters)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bradykinin (5- or 30-minute intervals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bradykinin (various doses)
Number of subjects: 0
Study: 6279061

Group type: EXPERIMENTAL
Intervention: Topical administration of delta 9-tetrahydrocannabinol (THC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study: 30501481

Group type: COMPARATOR
Intervention: Bendamustine plus rituximab
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 547
Study: 27080315

Group type: EXPERIMENTAL
Intervention: Inter-arm blood pressure difference (IAD) ≥5 mmHg
Number of subjects: 3350

Group type: EXPERIMENTAL
Intervention: Inter-arm blood pressure difference (IAD) ≥10 mmHg
Number of subjects: 3350

Group type: EXPERIMENTAL
Intervention: Inter-arm blood pressure difference (IAD) ≥15 mmHg
Number of subjects: 3350
Study: 25023784

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (30 mg/day of elemental iron for 12 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Iron bis-glycinate chelate (30 mg/day of elemental iron for 12 weeks)
Number of subjects: 200
Study: 22180580

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine replacement therapy (15 mg for 8 weeks)
Number of subjects: 925
Study: 20686324

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control (non-pioglitazone group)
Number of subjects: 186
Study: 18665187

Group type: EXPERIMENTAL
Intervention: Quality-of-life diagnosis and therapy (QoL system) implemented for breast cancer patients.
Number of subjects: 0
Study: 17132382

Group type: EXPERIMENTAL
Intervention: treatment protocol based on a formalised expert opinion
Number of subjects: 208

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 208
Study: 12965976

Group type: EXPERIMENTAL
Intervention: Health enhancement programs in elderly populations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11095656

Group type: EXPERIMENTAL
Intervention: High dialysate sodium concentration (H-Na(D))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dialysate sodium concentration (L-Na(D))
Number of subjects: 0
Study: 8897029

Group type: EXPERIMENTAL
Intervention: Exercise (continuous incremental cycling protocol at 55%, 70%, and 85% VO2peak)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Exercise (initial 6 min)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Exercise (at 70% and 85% VO2peak)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Exercise (at 12 min and 18 min)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 64
Study: 1841409

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (Intron A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 6346029

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 0
Study: 30461510

Group type: EXPERIMENTAL
Intervention: Surgical intervention for medial humeral epicondyle fractures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 0
Study: 29411722

Group type: EXPERIMENTAL
Intervention: 1200 mg gabapentin tablet (Group G, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo tablet (Group P, n = 50)
Number of subjects: 100
Study: 26409714

Group type: EXPERIMENTAL
Intervention: KatGuide method
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional forceps method
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: KatGuide method (experienced operators)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional forceps method (experienced operators)
Number of subjects: 109
Study: 25128249

Group type: EXPERIMENTAL
Intervention: Stress induction
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Paranoia induction
Number of subjects: 117

Group type: COMPARATOR
Intervention: No induction
Number of subjects: 117
Study: 23262451

Group type: EXPERIMENTAL
Intervention: Inhaled MgSO(4)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: β(2‐)agonist
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Inhaled MgSO(4) + β(2‐)agonist
Number of subjects: 76

Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 76
Study: 19926254

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pregabalin (PGB) 75mg
Number of subjects: 12
Study: 17621471

Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) under missing at random (MAR) assumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted average of parameter estimates from MI under MAR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed alternative method for NMAR
Number of subjects: 0
Study: 15924595

Group type: EXPERIMENTAL
Intervention: D2 gastrectomy with splenectomy and distal pancreatectomy
Number of subjects: 33
Study: 12683469

Group type: EXPERIMENTAL
Intervention: 4 h sleep per night for 14 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 6 h sleep per night for 14 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0 h sleep for 3 days (total sleep deprivation)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 6 h or less sleep per night
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cumulative wakefulness in excess of 15.84 h
Number of subjects: 48
Study: 10234493

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (n = 22)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lignocaine 1% (n = 21)
Number of subjects: 68

Group type: COMPARATOR
Intervention: 0.9% NaCl (saline) (n = 20)
Number of subjects: 68
Study: 8572664

Group type: EXPERIMENTAL
Intervention: 10 mg of deprenyl and/or 2,000 mg of tocopherol/day
Number of subjects: 800
Study: 1711001

Group type: EXPERIMENTAL
Intervention: Interferon administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (patients who became RNA negative but exhibited RNA again)
Number of subjects: 16
Study: 6261607

Group type: EXPERIMENTAL
Intervention: 50% glucose (0.5 g/kg/h) and insulin (250 U/1,000 cc) with additional insulin up to 200 U/h, maximum 800 U/10 h; 500 ml 10% crystalline amino acid solution on the 1st postoperative day.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ringer lactate as postoperative infusion (RL-group).
Number of subjects: 22
Study: 31420398

Group type: EXPERIMENTAL
Intervention: High-Intensity Treatment (HIT) - behaviour therapy, coaching and pharmacological advice
Number of subjects: 294

Group type: COMPARATOR
Intervention: High-Intensity Treatment (HIT)
Number of subjects: 294
Study: 28041600

Group type: EXPERIMENTAL
Intervention: Outcome Prioritisation Tool (OPT) consultation with GP
Number of subjects: 168

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 168
Study: 26912576

Group type: EXPERIMENTAL
Intervention: Sternal cables (Pioneer cabling system®)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Sternal wires (traditional sternal wiring in figure‐8 formation)
Number of subjects: 273
Study: 25077420

Group type: EXPERIMENTAL
Intervention: 20-μg rLP2086 dose
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 60-μg rLP2086 dose
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 46
Study: 22361329

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 343466

Group type: EXPERIMENTAL
Intervention: Model prediction
Number of subjects: 343466
Study: 19027312

Group type: EXPERIMENTAL
Intervention: Presence of coronary collaterals
Number of subjects: 281
Study: 17848425

Group type: EXPERIMENTAL
Intervention: ISIS 301012 50-400 mg administered weekly via subcutaneous injection for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISIS 301012
Number of subjects: 0
Study: 15250199

Group type: EXPERIMENTAL
Intervention: Combined therapy of shenmai and compound danshen injection (SM‐DS) before and after PCI
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison between treated and control groups
Number of subjects: 38
Study: 12583341

Group type: EXPERIMENTAL
Intervention: He Jie Decoction (HJD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual western medicine (Control)
Number of subjects: 45
Study: 9825335

Group type: EXPERIMENTAL
Intervention: ThinLine coradial bipolar leads
Number of subjects: 1068
Study: 7847099

Group type: EXPERIMENTAL
Intervention: Flutamide (750 mg orally daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 2483401

Group type: EXPERIMENTAL
Intervention: m‐BNCOD (mitoxantrone)
Number of subjects: 70

Group type: COMPARATOR
Intervention: m‐BACOD (doxorubicin)
Number of subjects: 70
Study: 1255259

Group type: EXPERIMENTAL
Intervention: Squibb Iodotope Diagnostic capsules
Number of subjects: 125

Group type: COMPARATOR
Intervention: Squibb Iodotope Oral liquid
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Radiocaps I‐131 (Abbott Laboratories)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Iodotope Oral liquid
Number of subjects: 125
Study: 31434076

Group type: EXPERIMENTAL
Intervention: Bortezomib and Vorinostat (BV) therapy post-ASCT for 12 cycles (28-day cycles)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bortezomib and Vorinostat (BV) therapy post-ASCT
Number of subjects: 30
Study: 31391201

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study: 28515056

Group type: EXPERIMENTAL
Intervention: Movement control exercise programme
Number of subjects: 3188

Group type: EXPERIMENTAL
Intervention: Movement control exercise programme (completed three or more weekly sessions)
Number of subjects: 3188

Group type: COMPARATOR
Intervention: Standardised control exercise programme
Number of subjects: 3188

Group type: COMPARATOR
Intervention: Overall match injury incidence
Number of subjects: 3188
Study: 25400146

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) infusion over 40 min
Number of subjects: 36
Study: 23906260

Group type: EXPERIMENTAL
Intervention: Repeated screening for psychosocial and behavioural risks during pregnancy
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Initial screening for psychosocial and behavioural risks during pregnancy
Number of subjects: 1044
Study: 21807250

Group type: EXPERIMENTAL
Intervention: Tiotropium (5 μg daily)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 μg twice daily)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 18930379

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 0
Study: 16452355

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (1 mg/kg every 8 hours for 5 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 48
Study: 15280144

Group type: EXPERIMENTAL
Intervention: Standard FHR monitoring with ST segment analysis
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard FHR monitoring without ST segment analysis
Number of subjects: 51
Study: 11375843

Group type: EXPERIMENTAL
Intervention: Tramadol (initial dose 100 mg, can increase to 200 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Morphine (initial dose 5 mg for body weight ≤ 70 kg or 10 mg for body weight > 70 kg, can increase to 15 or 20 mg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 105
Study: 9231856

Group type: EXPERIMENTAL
Intervention: Absorbable mesh (Polyglycolic acid, Dexon, Davis & Geck)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non‐absorbable mesh (Polypropylene, Prolene, Ethicon Ltd)
Number of subjects: 37
Study: 8115696

Group type: EXPERIMENTAL
Intervention: Naloxone 2 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 3309251

Group type: EXPERIMENTAL
Intervention: Rodogyl for 2 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 31009097

Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint (ARS)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint (ARS) with physical TMJ closed-lock reduction
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conservative therapy without ARS (Control)
Number of subjects: 69
Study: 29089370

Group type: EXPERIMENTAL
Intervention: Capsaicin (the major spicy component of chili pepper)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enjoyment of spicy foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (subjects who disliked spicy food)
Number of subjects: 0
Study: 25262454

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2289
Study: 23679347

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 200 μg BID
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg BID
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 22050796

Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg at 3.3 mg/sec after normal saline pretreatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg at 3.3 mg/sec after lidocaine 0.5 mg/kg pretreatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg at 3.3 mg/sec after lidocaine 1.0 mg/kg pretreatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg at 50 mg/sec after normal saline pretreatment
Number of subjects: 120
Study: 18516457

Group type: EXPERIMENTAL
Intervention: 10% mannitol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium picosulphate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (10% mannitol, sodium phosphate, sodium picosulphate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 16517330

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) and succinylcholine (1 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) and rocuronium (1 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg/kg) and succinylcholine (1 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg/kg) and rocuronium (1 mg/kg)
Number of subjects: 120
Study: 15052769

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel combined with micronized progesterone (MP) or medroxyprogesterone acetate (MPA) for 25 days per month
Number of subjects: 60
Study: 10779019

Group type: EXPERIMENTAL
Intervention: Visual stimulation with a yellow-blue annular checkerboard reversing at frequencies of 1, 4, or 8 Hz
Number of subjects: 12
Study: 9553982

Group type: EXPERIMENTAL
Intervention: Cetirizine (active treatment)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 817
Study: 8463453

Group type: EXPERIMENTAL
Intervention: 4 or 8 mg of sublingual buprenorphine for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single doses of cocaine (30 mg intravenously) and morphine (10 mg intravenously)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Daily maintenance on buprenorphine
Number of subjects: 20
Study: 3710059

Group type: EXPERIMENTAL
Intervention: Oleic acid (4.3 g/100 ml)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 13
Study: 30907272

Group type: EXPERIMENTAL
Intervention: Elective open surgical repair
Number of subjects: 19489

Group type: EXPERIMENTAL
Intervention: Elective endovascular aortic repair
Number of subjects: 19489

Group type: EXPERIMENTAL
Intervention: Ruptured open surgical repair
Number of subjects: 19489

Group type: EXPERIMENTAL
Intervention: Ruptured endovascular aortic repair
Number of subjects: 19489

Group type: COMPARATOR
Intervention: DREAM and EVAR-1 trials impact on elective open surgical repair
Number of subjects: 19489
Study: 29971397

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 19009

Group type: COMPARATOR
Intervention: Liquid-based cytology (LBC) testing
Number of subjects: 19009
Study: 27601892

Group type: EXPERIMENTAL
Intervention: Tele-rehab (telephone health-mentoring targeting home-based walking)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (waiting time before PR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Supervised exercise (part of PR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Participants not attending supervised exercise
Number of subjects: 40
Study: 24573909

Group type: EXPERIMENTAL
Intervention: Electronic containers for medication
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard packaging for medication
Number of subjects: 226
Study: 21756152

Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser therapy (FLT) combined with intermittent daily topical bleaching (5 treatments)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intermittent regimen of topical bleaching alone
Number of subjects: 14
Study: 21302191

Group type: EXPERIMENTAL
Intervention: Nucleoplasty
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Disc Dekompressor
Number of subjects: 126
Study: 17373163

Group type: EXPERIMENTAL
Intervention: 3-msec alexandrite laser treatment with fluences between 8 and 32 J/cm2
Number of subjects: 31

Group type: COMPARATOR
Intervention: Laser only treated area
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Laser/TCS treated area
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (TCS) cream (betamethasone dipropionate)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 3-msec alexandrite laser treatment
Number of subjects: 31
Study: 16115312

Group type: EXPERIMENTAL
Intervention: Task-based, community oriented teaching model in family medicine (experimental model)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard teaching curriculum (control group)
Number of subjects: 84
Study: 12381083

Group type: EXPERIMENTAL
Intervention: Intravenous administration of vitamin C
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patients with a history of KD (no gamma globulin treatment)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 39
Study: 11067699

Group type: EXPERIMENTAL
Intervention: Community-based educational intervention for urinary incontinence (specific details on dosage and duration not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait control condition
Number of subjects: 0
Study: 8986207

Group type: EXPERIMENTAL
Intervention: Low alcohol dose (0.48 g/kg/LBM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderate alcohol dose (0.72 g/kg/LBM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1336131

Group type: EXPERIMENTAL
Intervention: LMWH/DHE (low-molecular weight heparin 1,500 U-aPTT plus dihydroergotamine 0.5 mg, once a day)
Number of subjects: 179

Group type: COMPARATOR
Intervention: HDHE (sodium heparin 5,000 U plus dihydroergotamine 0.5 mg, twice a day)
Number of subjects: 179
Study: 6725660

Group type: EXPERIMENTAL
Intervention: Psoralens and ultraviolet A (PUVA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ultraviolet B (UVB)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of PUVA and UVB
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cumulative doses of PUVA and UVB
Number of subjects: 42
Study: 31206066

Group type: EXPERIMENTAL
Intervention: Physician facecard
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Whiteboard with attending name
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Facecard and whiteboard
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Facecard (hospitalists' perspective)
Number of subjects: 149
Study: 30335875

Group type: EXPERIMENTAL
Intervention: Papillary thyroid cancer terminology
Number of subjects: 550

Group type: COMPARATOR
Intervention: Papillary lesion terminology
Number of subjects: 550

Group type: COMPARATOR
Intervention: Abnormal cells terminology
Number of subjects: 550
Study: 27075606

Group type: EXPERIMENTAL
Intervention: 3D virtual image guidance (3DV)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional cross-sectional computed tomography (CT) image guidance
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-volume surgeons
Number of subjects: 37
Study: 25183657

Group type: EXPERIMENTAL
Intervention: Cholecalciferol therapy (50,000 IU twice weekly)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (normal kidney function), n=15
Number of subjects: 15
Study: 23044477

Group type: EXPERIMENTAL
Intervention: Distal scaphoid excision followed by DIC ligament excision
Number of subjects: 10

Group type: COMPARATOR
Intervention: DIC ligament excision alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Distal scaphoid excision after DIC ligament excision
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (original location before intervention)
Number of subjects: 10
Study: 19778914

Group type: EXPERIMENTAL
Intervention: Intranasal HC gp-39 (30, 150, 300, or 600 microg, once a week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18364685

Group type: EXPERIMENTAL
Intervention: Home visits for dietary advice
Number of subjects: 376

Group type: COMPARATOR
Intervention: Routine assistance from paediatricians (Control)
Number of subjects: 376
Study: 15932704

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 1004